Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1369)	3/22/2001 12:36:23 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 1826

MGI Pharma Begins New Irofulven Ovarian Cancer Phase 2 Dow Jones Newswires MINNEAPOLIS -- MGI Pharma Inc. (MOGN) began a new Phase 2 clinical trial of Irofulven, its novel anti-cancer compound, for patients with refractory or recurrent advanced epithelial ovarian cancer. In a press release Thursday, the company said the multi-center Phase 2 trial will evaluate the product using an every-other-week dosing schedule in up to 65 patients, to develop recommendations for an anticipated Phase 3 trial with Irofulven in advanced ovarian cancer. According to MGI, further development of the drug was prompted by tumor shrinkage and a complete response in an ovarian cancer patient using the every-other-week dosing schedule in a dose optimization trial. The patient enrollment period for the Phase 2 trial is expected to last about 12-to-18 months. The National Cancer Institute is conducting a Phase 2 trial of Irofulven for the treatment of ovarian cancer in patients with recurrent or persistent disease. Irofulven was administered daily for four-to-five days every 28 days. The the principal investigator for that trial concluded that Irofulven is an active agent in ovarian cancer patients with recurrent or persistent disease and that further studies are warranted, the pharmaceutical company said.